Centrexion Therapeutics Corporation (Centrexion), a company focused on developing non-opioid and non-addictive therapies for the treatment of chronic pain, today announced it will present one poster and one oral presentation on CNTX-4975 at the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) 2018 Annual Meeting taking place from October 19 “ 24 in Chicago, Illinois.
Full abstracts are available at http://acrabstracts.org. Details of the presentations are listed below.
Poster Abstract Title (#1367): Efficacy of Intra-Articular CNTX-4975 for Knee Osteoarthritis (OA) Pain Varies with Radiographic Presence of OA in the Opposite Knee Session Title: Osteoarthritis “ Clinical Poster II Session Type: ACR Poster Session B Presentation Time: Monday, October 22, 2018, 9:00AM-11:00AM CDT
Presentation Abstract Title (#1922): Characterization of the Pharmacology and Pharmacokinetics of CNTX-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe Knee OA Pain Session Title: 4M103 ACR Abstract: Pain Mechanisms“Basic & Clinical Science (1917“1922) Session Type: ACR Concurrent Abstract Session Presentation Time: Monday, October 22, 2018, 4:30PM-6:00PM CDT
Osteoarthritis (OA) is the most common joint disease in the United States, currently affecting more than 30 million Americans, according to the U.S. Centers for Disease Control. OA occurs when cartilage, the tissue that envelops the structural bones within a joint, gradually deteriorates. These changes cause pain, swelling and problems moving the joint. Although OA can affect any joint, it most often affects joints in the knees, hips, lower back and neck, small joints of the fingers and the bases of the thumb and big toe. Over time, patients with knee OA tend to become inactive due to pain and joint stiffness and reduced function.
CNTX-4975, Centrexions most advanced product candidate, is a synthetic, ultra-pure intra-articular injection of trans-capsaicin for the treatment of moderate to severe pain associated with knee OA. CNTX-4975 is designed to be administered directly into the joint where the pain stimulus originates and to selectively and locally target and disrupt the signaling of pain-sensing nerve fibers. In January 2018, CNTX-4975 was granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of pain associated with knee OA.
Centrexion is a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Centrexions website address is http://www.centrexion.com.